Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case‐series analysis from the Italian Rare Cancers Network
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34083
Abstract: To report on a retrospective case‐series analysis of weekly cisplatin (wCDDP) as a single agent or combined with imatinib (wCDDP/I) in patients with advanced chordoma treated within the Italian Rare Cancer Network. read more here.
Keywords: weekly cisplatin; case series; italian rare; advanced chordoma ... See more keywords
A modified olanzapine-based anti-emetic regimen for the control of nausea and vomiting in patients receiving weekly cisplatin
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Clinical Pharmacy"
DOI: 10.1007/s11096-020-00997-3
Abstract: Background There is limited data on specific antiemetic protocols for control of chemotherapy-induced nausea/vomiting (CINV) caused by weekly cisplatin regimens. Olanzapine is an active agent against CINV and may offer better control of nausea compared… read more here.
Keywords: cisplatin; patients receiving; control nausea; weekly cisplatin ... See more keywords
High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck.
Sign Up to like & getrecommendations! Published in 2017 at "Oral oncology"
DOI: 10.1016/j.oraloncology.2017.01.010
Abstract: OBJECTIVES To compare the outcomes and toxicity of high-dose cisplatin (HDC) versus weekly cisplatin (WC) definitive chemoradiotherapy (CRT) for patients with human papillomavirus (HPV) related oropharyngeal squamous cell carcinoma (SCCOPx). METHODS All patients with p16… read more here.
Keywords: high dose; cisplatin; versus weekly; cisplatin definitive ... See more keywords
Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.01293
Abstract: PURPOSE The standard treatment for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly cisplatin (100 mg/m2). However, whether chemoradiotherapy with weekly cisplatin (40 mg/m2) yields comparable… read more here.
Keywords: weekly cisplatin; noninferiority; chemoradiotherapy weekly; phase iii ... See more keywords
Clinical profile and outcomes in cervical cancer: An audit from a tertiary cancer center
Sign Up to like & getrecommendations! Published in 2022 at "Indian Journal of Cancer"
DOI: 10.4103/ijc.ijc_211_19
Abstract: Background: Carcinoma cervix contributes to a major proportion of cancer treatment in tertiary oncology centers. The outcomes are dependent on multiple factors. We conducted an audit to establish the pattern of treatment practiced for carcinoma… read more here.
Keywords: weekly cisplatin; audit; overall survival; carcinoma cervix ... See more keywords
A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cancer"
DOI: 10.7150/jca.21357
Abstract: Purpose: To compare the long-term survival outcomes and acute toxicity between locoregionally advanced nasopharyngeal carcinoma (NPC) patients who received either weekly or 3-weekly cisplatin during concurrent chemoradiotherapy (CCRT). Methods: Between November 2008 and August 2011,… read more here.
Keywords: locoregionally advanced; cisplatin; advanced nasopharyngeal; nasopharyngeal carcinoma ... See more keywords